Revance Therapeutics Inc (RVNC)

[DewDiligence]

My 3Q23 revenue expectation is essentially the same as yours: $53M, roughly half Daxxify and half RHA.* Inasmuch as 2Q23 revenue excluding HintMd was $54.4M, selling $53M during the seasonally slow third calendar quarter would effectively be an increase relative to 2Q23 is the projected annualized rate.

In 4Q23, which is seasonally the strongest calendar quarter for aesthetics, I expect revenue of $90M+ and I would not be surprised to see a doubling of revenue relative to 3Q23.

*I'm assuming RVNC applies July/August HintMD revenue to a separate line of the income statement called, Loss from discontinued operations.